Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.11889/8025
Title: Development and Validation of a Stability-Indicating HPLC Method for the Simultaneous Determination of Florfenicol and Flunixin Meglumine Combination in an Injectable Solution
Authors: Batrawi, Nidal 
Naseef, Hani 
Al-Rimawi, Fuad 
Keywords: High performance liquid chromatography;Drugs - Analysis;Pharmaceutical preparations - Analysis.;Drug stability;Anti-infective agents - Usage;Nonsteroidal anti-inflammatory agents
Issue Date: 2017
Abstract: The combination of the powerful antimicrobial agent florfenicol and the non steroidal anti-inflammatory flunixin meglumine is used for the treatment of bovine respiratory disease (BRD) and control of BRD-associated pyrexia, in beef and non lactating dairy cattle. This study describes the development and validation of an HPLC - UV method for the simultaneous determination of florfenicol and flunixin, in an injectable preparation with a mixture of excipients. The proposed RP-HPLC method was developed by a reversed phase (RP-) C18e (250mm×4.6mm,5𝜇m) column at room temperature, with an isocratic mobile phase of acetonitrile and water mixture, and pH was adjusted to 2.8 using diluted phosphoric acid, a flow rate of 1.0m L/min, and ultraviolet detection at268nm. The stability-indicating method was developed by exposing the drug stostress conditions of acid and base hydrolysis, oxidation, photodegradation, and thermal degradation; the obtained degraded products were successfully separated from the APIs. This method was validated in accordance with FDA and ICH guidelines and showed excellent linearity, accuracy, precision, specificity, robustness, LOD, LOQ, and system suitability results within the acceptance criteria.
URI: http://hdl.handle.net/20.500.11889/8025
Appears in Collections:Fulltext Publications

Show full item record

Page view(s)

27
checked on Jun 27, 2024

Download(s)

4
checked on Jun 27, 2024

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.